Xinyin Liu

1.7k total citations · 2 hit papers
14 papers, 1.2k citations indexed

About

Xinyin Liu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Xinyin Liu has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Xinyin Liu's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer-related molecular mechanisms research (3 papers). Xinyin Liu is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer-related molecular mechanisms research (3 papers). Xinyin Liu collaborates with scholars based in China. Xinyin Liu's co-authors include Renhua Guo, Shidai Jin, Yi Chen, Chen Zhang, Xiyi Lu, Wei Wang, Erbao Zhang, Kun Xu, Xuezhi He and Jiaqi Yao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Oncogene and Molecular Cancer.

In The Last Decade

Xinyin Liu

12 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

2022 907 citations Chen Zhang, Xinyin Liu et al. Molecular Cancer profile →
Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop

2025 19 citations Chen Zhang, Wenxin Zhou et al. Oncogene profile →

Peers

Countries citing papers authored by Xinyin Liu

Since Specialization

Citations

This map shows the geographic impact of Xinyin Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinyin Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinyin Liu more than expected).

Fields of papers citing papers by Xinyin Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinyin Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinyin Liu. The network helps show where Xinyin Liu may publish in the future.

Co-authorship network of co-authors of Xinyin Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xinyin Liu. A scholar is included among the top collaborators of Xinyin Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinyin Liu. Xinyin Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	GLMP promotes EGFR-TKI resistance by activating autophagy and RhoA pathway in non-small cell lung cancer 2025 ·npj Precision Oncology ·Xiaowen Liang, Jiali Xu, Songren Shu, Wei Lv, Dandan Yin, Shuying Miao, Xiyi Lu, Chen Zhang, Xinyin Liu, (unknown), Jun Li, (unknown), Erbao Zhang, Renhua Guo	0
2	Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop breakdown → 2025 ·Oncogene ·Chen Zhang, Wenxin Zhou, (unknown), Jiali Xu, Jun Li, Xinyin Liu, Xiyi Lu, (unknown), (unknown), (unknown), Erbao Zhang, (unknown)	19
3	Carbonic Anhydrase IX Controls Vulnerability to Ferroptosis in Gefitinib-Resistant Lung Cancer 2023 ·Oxidative Medicine and Cellular Longevity ·(unknown), Xiyi Lu, Xinyin Liu, Jiali Xu, (unknown), (unknown), (unknown), Renhua Guo	14
4	Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR‐TKIs in advanced non‐small cell lung cancer: A systematic review and network meta‐analysis 2023 ·Thoracic Cancer ·(unknown), Xinyin Liu, Jun Li, Tianyu Qu, Yanan Cui, Shidai Jin, Erbao Zhang, Renhua Guo	2
5	Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer 2022 ·Frontiers in Oncology ·Yanan Cui, Xinyin Liu, (unknown), Liang Xiao, (unknown), Zhihong Zhang, Renhua Guo	8
6	Ferroptosis in cancer therapy: a novel approach to reversing drug resistance breakdown → 2022 ·Molecular Cancer ·Chen Zhang, Xinyin Liu, Shidai Jin, Yi Chen, Renhua Guo	907
7	Copy number amplification and SP1-activated lncRNA MELTF-AS1 regulates tumorigenesis by driving phase separation of YBX1 to activate ANXA8 in non-small cell lung cancer 2022 ·Oncogene ·Xiyi Lu, Jing Wang, Wei Wang, Chenfei Lu, Tianyu Qu, Xuezhi He, Xinyin Liu, Renhua Guo, Erbao Zhang	37
8	Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors. 2022 ·PubMed ·Yanan Cui, Pengpeng Zhang, Xiaowen Liang, Jiali Xu, Xinyin Liu, (unknown), Junling Zhang, Wei Wang, Fang Zhang, Renhua Guo	21
9	Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis 2022 ·Journal for ImmunoTherapy of Cancer ·Wen Gao, Lingxiang Wu, Shidai Jin, Jun Li, Xinyin Liu, Jiali Xu, Wei Zhang, Qixing Gong, Chunxiao Sun, Wei Wang, Zidun Wang, Yang Shao, Jiani C. Yin, (unknown), Liang Chen, Qianghu Wang, Renhua Guo	7
10	Association of <i>KDR</i> Mutation With Better Clinical Outcomes in Pan-Cancer for Immune Checkpoint Inhibitors 2021 ·SSRN Electronic Journal ·Yanan Cui, Pengpeng Zhang, Xiao Liang, Jiali Xu, Xinyin Liu, (unknown), Junling Zhang, Wei Wang, Fang Zhang, Renhua Guo	0
11	[Progress in Role of FEZF1-AS1 in Non-small Cell Lung Cancer]. 2020 ·SHILAP Revista de lepidopterología ·Jin Chen, Rong Yin, Xinyin Liu	1
12	LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC 2019 ·Molecular Therapy — Nucleic Acids ·Xinyin Liu, Xiyi Lu, Fuxi Zhen, Shidai Jin, Tongfu Yu, Quan Zhu, Wei Wang, Kun Xu, Jiaqi Yao, Renhua Guo	100
13	EZH2-Mediated Epigenetic Suppression of GDF15 Predicts a Poor Prognosis and Regulates Cell Proliferation in Non-Small-Cell Lung Cancer 2018 ·Molecular Therapy — Nucleic Acids ·Xiyi Lu, Xuezhi He, Jun Su, Jing Wang, Xinyin Liu, Kun Xu, Wei De, Erbao Zhang, Renhua Guo, Yuenian Eric Shi	30
14	A Novel Long Non-Coding RNA, SOX21-AS1, Indicates a Poor Prognosis and Promotes Lung Adenocarcinoma Proliferation 2017 ·Cellular Physiology and Biochemistry ·Xiyi Lu, Chenjun Huang, Xuezhi He, Xinyin Liu, (unknown), Erbao Zhang, Wei Wang, Renhua Guo	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact